• Our supF forward mutation assay revealed for

  2022-06-14

  

  Our supF forward mutation assay revealed, for the first time, that 5OHU predominantly induced the C→T mutation in human cells. The mechanism underlying the induction of the C→T mutation in human cells by 5OHU remains unclear, however, the finding that 5OHU predominantly induced the C→T mutation was

• Medulloblastoma predominantly occurs in infants and

  2022-06-14

  

  Medulloblastoma predominantly occurs in infants and children, and is the most-common type of paediatric malignant INCB 018424 tumour, accounting for about 20% of all childhood brain tumors [63]. According to cancer genomics, medulloblastoma consists of at least 4 distinct subgroups: Hh driven, Wnt d

• Although GLP has greater insulin releasing effects at pharma

  2022-06-14

  

  Although GLP-1 has greater insulin-releasing effects at pharmacological concentrations [10], it is apparent that the higher circulating concentrations of GIP combined with more pronounced increase in secretion following feeding make GIP the major physiological incretin [7], [11]. The peptide exerts

• Most of the tumors showed relatively

  2022-06-14

  

  Most of the tumors showed relatively higher GalR1 mRNA levels than the controls (Fig. 1a, Table 3). However one patient with the lower GalR1 mRNA levels (#12) had, in fact, relatively lower levels of transcript for galanin and the other galanin receptors. Patient #10 and 4 who were also expressing l

• Many neutral and acidophilic galactosidases have been purifi

  2022-06-14

  

  Many neutral and acidophilic β-galactosidases have been purified from microorganisms [14], while only a few alkalophilic β-galactosidases have been reported [19]. An alkalophilic β-galactosidase, BGal_375, was obtained and researched for the characterization of its hydrolytic activity. BGal_375 show

• Recently a lot of synthetic FFA agonists containing acidic

  2022-06-14

  

  Recently, a lot of synthetic FFA1 agonists containing acidic moieties have been reported (Fig. 1) [13], [14], [15], [16], [17], [18], [19], [20], [21]. Notably, most of FFA1 agonists usually have the common biphenyl scaffold, which resulted in a relative deprivation in structure types of agonists [2

• Albumin is the major carrier of

  2022-06-14

  

  Albumin is the major carrier of free fatty acids (FFAs) in plasma [59], and harbours seven binding sites that are common to FFAs with a range of chain-lengths (C10-C18) across its three domains (Fig. 1a) [60,61]. In vitro, saturated, mono- and poly-unsaturated FFAs, with chain lengths ranging from C

• This excellent tolerability is especially interesting in the

  2022-06-14

  

  This excellent tolerability is especially interesting in the light of the fact that intravenous administration of liposomal ponatinib was predicted to yield much higher plasma concentrations as compared to the orally administered free drug. In addition, liposomal drug dose in absolute numbers was te

• TIC10 sale br Acknowledgements We thank Dr Bhushan

  2022-06-14

  

  Acknowledgements We thank Dr. Bhushan Nagar and Dr. Albert Berghuis for access to the X-ray diffraction machine at McGill University. We also thank Dr. Manon Couture and Dr. Steve Charette at Université Laval for access to scientific equipment. Funding for this research was provided by Discovery

• br Role of funding source br Conflict of interest br

  2022-06-14

  

  Role of funding source Conflict of interest Acknowledgements We thank F. Blaskovits and P. Kesner for technical assistance. This project was supported by operating grants from the Canadian Institutes of Health Research (CIHR) to X. Zhang (MOP123249) and the National Natural Science Foundati

• br Introduction It is well known that

  2022-06-14

  

  Introduction It is well known that conventional cancer treatment strategies, such as surgery, radiotherapy, and chemotherapy all have their own limitations, which lead to an unsatisfactory therapeutic effect. Under this situation, the combination of two or more therapeutic strategies has recently

• A second H R antagonist with benzamide based structure from

  2022-06-13

  

  A second H3R antagonist with benzamide-based structure from Johnson & Johnson is JNJ-31001074, known as Bavisant and under chemical IUPAC name of (4-cyclopropylpiperazin-1-yl)-[4-(morpholin-4-ylmethyl)phenyl]methanone. It is a compound with molecular weight 329.44, HBA four, and MLogP 1.52 encompass

• br Materials and methods br

  2022-06-13

  

  Materials and methods Results Discussion Several histamine H3 receptor antagonists have progressed into clinical development for indications including Alzheimer's disease, schizophrenia, pain and narcolepsy. Each of the compounds studied herein has been extensively characterized in its own

• br Acknowledgments This study was financially supported by N

  2022-06-13

  

  Acknowledgments This study was financially supported by National Science Center Poland grant No DEC-2011/02/A/NZ4/00031 (KKK), Jagiellonian University Medical College (Poland) grants: K/ZDS/007130 (SM) and K/ZDS/007131 (SM), COST Action CA15135 (DŁ, HS, KKK) and DFG INST 208/664-1 FUGG (HS). Than

• isoquercitrin Several studies have also shown that

  2022-06-13

  

  Several studies have also shown that HK2 may be an important downstream isoquercitrin of the PI3K/AKT/mTOR signaling pathway and may contribute to the development of cancer [15]. In our previous study, we found AKT2 expression was positively correlated with HK2 expression in primary colon cancer spe

13160 records 404/878 page Previous Next First page 上5页 401402403404405 下5页 Last page